InsiderTrades

Form 4 for CLNN Clene Inc.

Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-16 · accession 0001562180-23-005321 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-06-20 2023-06-16 CLNN MATLIN DAVID J Dir P - Purchase $0.8 +1.50M 6.79M +28% +$1.20M
DM 2023-06-20 2023-06-16 CLNN MATLIN DAVID J Dir A - Grant — +3.00M 1.50M New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-06-16 P A 1,500,000 $0.8 6,793,684 D — —
2 Derivative Warrants (Right to buy) 2023-06-16 A A 1,500,000 — 1,500,000 D $1.10 · 2023-06-16 to — 1,500,000 Common Stock (F2) The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. (F4) The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.
3 Derivative Warrants (Right to buy) 2023-06-16 A A 1,500,000 — 1,500,000 D $1.50 · 2023-06-16 to — 1,500,000 Common Stock (F2) The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. (F3) The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc.